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Conducting trials of novel interventions during 
infectious disease emergencies, such as the on-
going Covid-19 pandemic, is increasingly recog-
nized as important for determining the efficacy 
of potential vaccines and therapies. Clinical trials 
to evaluate investigational interventions are being 
implemented as part of the broader efforts to con-
trol the spread of an infectious disease and to 
improve patient outcomes. In such circumstances, 
however, it can be challenging to acquire the nec-
essary evidence about the effects of the interven-
tions to inform future patient care and public 
health planning, in part because of the unpredict-
able size, geographic location, and duration of 
outbreaks.1
To Publish or Not to Publish
Concern about publication bias has led to an 
emphasis on the need to report the results of all 
clinical trials, even those that end early with in-
conclusive results at the end of an outbreak. This 
principle is included in statements regarding the 
ethical framework of clinical trials, such as the 
Declaration of Helsinki. Following this principle, 
investigators in trials that were conducted during 
the 2014–2016 West African Ebola epidemic that 
were terminated early (without reaching predefined 
stopping criteria) because of waning transmission 
submitted the inconclusive results for publication 
as planned at the end of the trial.2-4 Avoidance of 
publication bias is essential for the development 
of good policy; nonetheless, publication of incon-
clusive results (e.g., from an underpowered study) 
can make it much more difficult to develop de-
finitive evidence about the efficacy and safety of 
the intervention under investigation.5,6
At the end of an outbreak, the release of prom-
ising but inconclusive results from partially com-
pleted trials may support the belief that confirma-
tory trials comparing the investigational agents 
with the previously accepted placebo or standard-
of-care comparator could no longer be conducted. 
This assumption can create a state of perpetual 
uncertainty about the true effect of both the 
previously tested agent (which may now be con-
sidered the standard of care) and any new agents 
that are being evaluated. This situation has oc-
curred, for example, with the routine off-label 
use of ribavirin for the treatment of Lassa fever7 
and of oseltamivir for the treatment of severe 
influenza.
In the randomized, controlled PREVAIL (Part-
nership for Research on Ebola Virus in Liberia) 
II trial of the triple monoclonal antibody cock-
tail ZMapp, the investigators concluded that 
“although the estimated effect of ZMapp ap-
peared to be beneficial, the result did not meet 
the prespecified statistical threshold for effica-
cy.” The evidence of efficacy clearly did not meet 
the conventional standards for licensure.4 Never-
theless, in 2018, during a large Ebola outbreak in 
the Democratic Republic of Congo (DRC), inves-
tigators used ZMapp rather than the standard-
of-care treatment as the control against which to 
compare other Ebola therapeutics in the random-
ized PALM trial (Investigational Therapeutics for 
the Treatment of People with Ebola Virus Disease).8
There is an obvious need to balance the impor-
tance of publishing the results of all completed 
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clinical trials against the potential adverse con-
sequences if the published results do not provide 
reliable answers to the questions that the trials 
were designed to address. Thus, a new approach 
to clinical trials is needed to enable reliable evalu-
ations of vaccines and treatments for outbreak 
pathogens.
Introducing the Core Protocol
As members of the R&D Blueprint,9 a work plan 
for designing clinical trials during public health 
emergencies, sponsored by the World Health Or-
ganization (WHO), we advocate the use of a “core 
protocol” in such cases. Core protocols (also called 
master protocols) have been described for simul-
taneous evaluation of multiple interventions or 
of a single intervention targeting multiple dis-
eases.10 We propose a core-protocol concept that 
allows a clinical trial to extend across multiple 
infectious disease outbreaks. This approach ac-
commodates the changing and unpredictable fea-
tures of an epidemic and incorporates new in-
vestigative team members into the trial over time.
To avoid a premature release of data, core 
protocols would specify that efficacy data from 
a trial that has not yet been completed because 
of insufficient enrollment should not be released. 
After an outbreak has ended at a given site, the 
trial would be paused. If so specified in the core 
protocol, an independent monitoring committee 
could review results from an interim analysis of 
trial data to make recommendations regarding 
whether the trial should continue or stop for ef-
ficacy, futility, or safety, as guided by a prespeci-
fied monitoring plan.11 Under the core protocol, 
the investigators would remain unaware of any 
results of the analyses; the trial data would be 
released only if the trial was stopped on the basis 
of a recommendation from the monitoring com-
mittee or had reached its targeted number of end-
point events or amount of participant follow-up.
Vaccine trials that are conducted for 2 years 
or more are commonly performed to combat dis-
eases with predictable seasonality, such as Lyme 
disease12 and Argentine hemorrhagic fever,13 with 
results withheld until the requisite numbers of 
events have been observed. Such studies provide 
some precedent, albeit imperfect, for our proposal, 
which differs in that it focuses on diseases with 
outbreaks that are less predictable, may not be 
observed every year, and may reemerge in a dif-
ferent location. Such diseases include those tar-
geted by the R&D Blueprint — including Ebola 
virus infection, Middle East respiratory syndrome, 
Lassa fever, and Nipah virus infection — that oc-
cur irregularly but nonetheless relatively frequent-
ly. For pathogens that may emerge only once a 
decade or even less frequently, this approach may 
not be practical.
The use of core protocols can facilitate the im-
plementation of clinical research across successive 
outbreaks. The PALM trial included a core-pro-
tocol framework to guard against the release of 
inconclusive data. If the outbreak in the DRC 
had waned before the conclusion of the trial, the 
trial would have continued without a release of 
the results, unless the data monitoring committee 
had recommended termination. Ultimately, the 
PALM trial was terminated during the DRC out-
break on the advice of the data monitoring com-
mittee when an interim analysis revealed that 
REGN-EB3 (another cocktail of three monoclo-
nal antibodies) was superior to ZMapp; improved 
survival was also associated with the monoclonal 
antibody mAb114 but not with the nucleotide 
analogue prodrug remdesivir.
Although the PALM trial was successful in 
identifying two promising therapeutics, there 
were limitations resulting from the use of ZMapp 
as the comparator group because its clinical ben-
efit had not been definitively established during 
the PREVAIL II trial. The overall evidence in sup-
port of REGN-EB3 and especially mAb114 would 
have been stronger if the drugs had been evalu-
ated against a standard-of-care group, as in the 
PREVAIL II trial, or a drug with known efficacy. 
Furthermore, the question remains whether ZMapp 
and remdesivir have any effect. Such findings 
would have been particularly valuable in settings 
in which the monoclonal antibody drugs were not 
available and would have had implications for the 
development of combination regimens. Finally, it 
is not clear how data from the PALM trial would 
have been interpreted if survival had been similar 
in patients receiving the other drugs and in those 
receiving ZMapp. These challenges could have 
been largely avoided if the PREVAIL II trial had 
been designed under a core protocol. It is likely 
that the results of the PREVAIL II trial would not 
have been published at the end of the epidemic, 
since they did not meet the prespecified level of 
evidence required, and the trial would have been 
restarted in the DRC with a standard-of-care group 
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in place plus ZMapp and additional investigational 
treatments. With accrued data from the DRC, the 
question of whether ZMapp was effective could 
have been answered, thus establishing a clearer 
benchmark for all candidate products. Such a 
framework could also have eliminated the need for 
a new protocol altogether.
Emphasis on Cooper ation  
and Coordination
The development of a core protocol involves a pre-
liminary step of engaging researchers and national 
representatives from affected countries in deter-
mining the primary research questions and main 
design elements. Since officials in the Ministry of 
Health and other governmental offices in affect-
ed countries will be under great political pressure 
to release the interim results of trials, their ap-
proval of the strategy is necessary. Ethics com-
mittees and regulatory agencies should be en-
gaged in the earliest stages of protocol planning. 
There must be a clear and transparent a priori 
mechanism for achieving consensus regarding 
elements of the protocol, such as the selection of 
investigational and control agents and the gover-
nance structures to oversee trial operations, man-
age data and samples, and mediate disagreements 
among the stakeholders. An international orga-
nization, such as the WHO, may be best suited for 
the responsibility of coordinating stakeholders 
and maintaining capacity for research over a time 
period of uncertain duration.
For each successive outbreak, study teams 
should be encouraged to collaborate on existing, 
ongoing protocols rather than starting new, in-
dependent trials. New investigational agents may 
be added to the protocol over time as they become 
available or may be removed as deemed appropri-
ate, using a platform trial approach, as described 
previously.10 Special consideration should be given 
to allowing flexibility in the study sample size, 
since some assumptions, such as the case fatality 
rate in therapeutics trials, may need to be revised 
over time. In the context of public health emer-
gencies in which there are substantial obstacles 
to developing reliable and meaningful evidence, 
we underscore the need for cooperation and co-
ordination among research stakeholders, includ-
ing funding agencies.9 These types of large-scale, 
multipartner projects are logistically complex, but 
there is precedent for them in other areas of 
clinical research, such as in cancer clinical tri-
als.10 Given the effect of the ongoing Covid-19 
pandemic, this message is especially timely. Core 
protocols are rapidly being developed by the WHO 
for trials assessing the efficacy of therapies and 
vaccines that are being developed to combat this 
infection. Implementing clinical trials for treat-
ments during disease outbreaks under a core pro-
tocol could increase the chances of efficiently 
generating reliable evidence to determine which 
therapies are effective, thus providing timely infor-
mation to public health officials and clinicians 
caring for patients.
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